Healthcare

Leading life science organisations and emerging healthcare companies trust Linklaters lawyers to help navigate them through the myriad of challenges to achieve their goals in a highly regulated and rapidly changing healthcare industry.

Linklaters has a long history of advising clients in the healthcare sector. We have developed strong working relationships and a deep understanding of our client’s business environment, enabling us to provide solutions orientated advice when managing and implementing highly complex, cross-border transactions and other business critical scenarios.

Our clients are many of the world’s biggest players in the healthcare sector, ranging from pharmaceutical, biotech, and medical equipment manufacturing organisations, through to healthcare services groups, banks, private equity houses and sovereign wealth funds.

Our healthcare expertise

Our clients draw on our expertise in all areas, including corporate finance, mergers and acquisitions, product commercialisation, supply chains, IP, tax, regulation, litigation, and antitrust. More specifically:

  • We can support our clients as they expand their businesses in both established and growth markets, whether through M&A, joint ventures, distribution agreements or by other means, including through the evolution into a digital world;
  • We have one of the world’s preeminent antitrust practices with a dedicated sector focus. We have unparalleled expertise and continued involvement in the highest profile and most complex antitrust cases at national, EU and global level, ranging from strategic M&A mandates to cutting-edge behavioural and regulatory assignments;
  • Our IP practice works with a number of healthcare companies protecting, enforcing and defending their IP rights. Our IP team includes highly experienced litigators and advisers on non-contentious commercial issues and agreements; and
  • We know the healthcare regulatory issues and have excellent relationships with specialist regulatory healthcare lawyers in key jurisdictions. We work closely with the firm’s other sector teams, especially our Consumer and Technology sectors, to anticipate and address industry convergence trends.

Our healthcare teams are based in many of the key business hubs across the Americas, Asia and Europe including Belgium, China, Germany, France, Singapore, the United Kingdom and the United States.

Related insights

Scroll to explore our related content

close up of test tubes

Digital Health

Close X
hand pressing screen

The MDR is here Regulatory changes and their impact on liability

Close X
scientist looking down microscope

The European Commission struck down on pharma pricing. Shook Aspen - and the whole forest?

Close X
Monitor

Covid-19: Supplying vital medical equipment in uncertain times and managing regulatory, contractual and reputational risk

Close X
molecules

Covid-19: Impact on EU Healthcare Regulation

Close X
   

Recent healthcare transactions

Gavi

Gavi on the establishment of the COVAX facility for the funding and allocation of Covid vaccines globally, including on its participation principles, its supplier volume commitment arrangements and other related arrangements and the interrelation between these and agreements with CEPI, BMGF and sovereign state participants.

Read our press release

Neuraxpharm

Apax Partners LLP on its auction sale process of Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of central nervous system disorders.

Read our press release

Bayer AG

Bayer AG in connection with its acquisition of UK-based biotech KaNDy Therapeutics Ltd, to expand its drug development pipeline in women’s healthcare.

Read our press release

Takeda

Takeda on the disposal of its haemostasis product TachoSil to Corza Health Inc for €350m.

Read our press release

Takeda

Takeda in relation to several ground-breaking matters, including its £46bn recommended offer for Shire plc, the largest ever outbound M&A deal by a Japanese company; and waiver from commitment to divest the development compound SHP-647, the first-ever European Commission waiver of a pipeline merger divestment commitment.

Read our press release

Bayer AG

Bayer AG on the US$7.6bn sale of its animal health business to Elanco Animal Health to create a leading global animal health company.

QIAGEN N.V.

QIAGEN N.V. on the aborted business combination agreement and the friendly takeover by the US technology group Thermo Fisher Scientific worth €10.4bn.

Ablynx

Ablynx on the €3.9bn offer by Sanofi to acquire all of its outstanding ordinary shares.

Nestlé Health Science

Nestlé Health Science on the drafting and negotiation of complex licence and supply agreements with Valbiotis, for the purposes of the development and global commercialisation of an innovative, patented dietary supplement, for diabetic and pre-diabetic patients.

Nestlé

Nestlé advising on the £7.8bn sale of its Skin Health division and related global supply and distribution arrangements.

Genomics England

Genomics England on a range of commercial, technology, public law, competition/state aid, privacy and corporate governance issues relating to its achievement of its public interest and commercial objectives. We also advised them in respect of their agreement with Illumina, who provided genome sequencing services to Genomics England, and key data privacy and technology issues arising out of such contracts.

Sanofi and Regeneron Pharmaceuticals

Sanofi and Regeneron Pharmaceuticals in a cross-border, “innovator vs innovator” patent litigation initiated in the US, the UK, France, Germany and beyond, in the field of therapeutic monoclonal antibodies.

Johnson & Johnson

Johnson & Johnson on several transactions, including its acquisition of Abbott Medical Optics (US$ 4.3 billion), Synthes (US$ 21.3 billion), Pfizer Consumer Healthcare (US$ 16.6 billion), and Guidant (US$ 21.1 billion), the sale of Codman Neurosurgery (US$ 1 billion), Ortho-Clinical Diagnostics Inc (US$ 4.15billion) and divestment of Cordis Corporation (US$ 2billion).

McKesson Corporation

McKesson Corporation advising this global leader in health care supply chain management solutions and retail pharmacy, on the sale of part of its European businesses to PHOENIX group. The transaction includes McKesson's subsidiaries in Belgium, France, Ireland, Italy, Portugal and Slovenia as well as its German-based AG headquarters in Stuttgart, its German wound-care business, its shared services center in Lithuania, and its 45% ownership stake in Brocacef, the company’s joint venture in the Netherlands.

Bupa

Bupa on its partnership with a virtual consultation app start-up, including on its investment in the start-up and its technology arrangements for development and distribution of customisations designed to give the provider a competitive advantage in a number of jurisdictions in Asia, Europe and the Middle East, including on the privacy, IT, commercial and medical device issues arising.